Theravance Biopharma, Inc. announced the appointment of Jim Kelly, Managing Director at Weiss Asset Management, the Company's second largest shareholder, to its Board of Directors. Mr. Kelly, 42, joined Weiss Asset Management (“WAM”) in November 2010, where he is currently a Managing Director and a member of the Investment Committee. Prior to joining WAM, Mr. Kelly worked at Farallon Capital Management, Madison Dearborn Partners and Lehman Brothers.

Mr. Kelly graduated cum laude from Duke University in 2002 with a BS in Economics and with minors in Math and Political Science. His knowledge of finance, strategy and capital markets, as well as his experience investing in public and private companies, contributed to the Board's conclusion that he should serve as a director. The following list summarizes certain of Mr. Kelly's notable attributes and experiences: corporate/business development/M&A; finance and accounting; international business; legal, policy, corporate governance; and strategic planning.

These attributes and experiences are among those identified in the section of the Proxy Statement titled “Board Diversity, Skills, Experience and Tenure.